FAZ053X
Total Payments
$362,791
Transactions
6
Doctors
0
Companies
1
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2020 | $27,845 | 1 | 0 |
| 2019 | $105,485 | 2 | 0 |
| 2018 | $156,879 | 2 | 0 |
| 2017 | $72,582 | 1 | 0 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $362,791 | 6 | 100.0% |
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| A PHASE I OPEN LABEL MULTI CENTER DOSE ESCALATION STUDY OF FAZ053 AS SINGLE AGENT AND IN COMBINATION WITH PDR001 IN ADULT PATIENTS WITH ADVANCED MALIGNANCIES | Novartis Pharmaceuticals Corporation | $362,791 | 0 |
Top Doctors Receiving Payments for FAZ053X
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| Unknown | — | New York, NY | $362,791 | 6 |
Ad
Manufacturing Companies
- Novartis Pharmaceuticals Corporation $362,791
Product Information
- Type Drug
- Total Payments $362,791
- Total Doctors 0
- Transactions 6
About FAZ053X
FAZ053X is a drug associated with $362,791 in payments to 0 healthcare providers, recorded across 6 transactions in the CMS Open Payments database. The primary manufacturer is Novartis Pharmaceuticals Corporation.
Payment data is available from 2017 to 2020. In 2020, $27,845 was paid across 1 transactions to 0 doctors.
The most common payment nature for FAZ053X is "Unspecified" ($362,791, 100.0% of total).
FAZ053X is associated with 1 research study, including "A PHASE I OPEN LABEL MULTI CENTER DOSE ESCALATION STUDY OF FAZ053 AS SINGLE AGENT AND IN COMBINATION WITH PDR001 IN ADULT PATIENTS WITH ADVANCED MALIGNANCIES" ($362,791).